Publication
2021
- Fakes, L., Hutcheson, I. and Knowlden, J. 2021. The role of the glucocorticoid receptor in anti-hormone resistance in breast cancer. The British Student Doctor Journal 5(1), pp. 18-31. (10.18573/bsdj.184)
2014
- Gee, J. M. W. et al. 2014. Increased Ret signalling and impact of vandetanib in acquired tamoxifen resistant breast cancer. Cancer Research 74(19), article number: 738. (10.1158/1538-7445.AM2014-738)
- Jordan, N. J. et al. 2014. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro. Breast Cancer Research 16(1), pp. -., article number: R12. (10.1186/bcr3604)
2011
- Hutcheson, I. R. et al. 2011. Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1. Breast Cancer Research 13(2), article number: R29. (10.1186/bcr2848)
- Gee, J. M. W. et al. 2011. Antihormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistance. Hormone Molecular Biology and Clinical Investigation 5(2), pp. 67-77. (10.1515/HMBCI.2011.009)
- Knowlden, J. M., Gee, J. M. W., Barrow, D., Robertson, J. F., Ellis, I. O., Nicholson, R. I. and Hutcheson, I. R. 2011. erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines. Breast Cancer Research 13(5), article number: R93. (10.1186/bcr3018)
2010
- Knowlden, J. M., Gee, J. M. W., Barrow, D., Robertson, J. F., Ellis, I. O., Nicholson, R. I. and Hutcheson, I. R. 2010. O-36 Recruitment of insulin receptor substrate-1 by erbB3 impacts on IGF-IR signalling in oestrogen receptor-positive breast cancer cells [Abstract]. EJC Supplements 8(6), pp. 13-14. (10.1016/j.ejcsup.2010.06.037)
- Knowlden, J. M., Gee, J. M. W., Barrow, D., Robertson, J. F., Ellis, I. O., Nicholson, R. I. and Hutcheson, I. R. 2010. Recruitment of insulin receptor substrate-1 by erbB3 impacts on IGF-IR signalling in oestrogen receptor-positive breast cancer cells [Abstract]. Breast Cancer Research 12(S1), pp. S15. (10.1186/bcr2546)
- Hutcheson, I. R., Goddard, L., Gee, J. M. W., Barrow, D. and Nicholson, R. I. 2010. Fulvestrant-induced expression of erbB3 and erbB4 sensitizes ER-positive breast cancer cells to heregulins [Abstract]. Breast Cancer Research 12(S1), article number: P13. (10.1186/bcr2510)
- Thomas, N. B. P., Hutcheson, I. R., Campbell, L., Gee, J. M. W., Taylor, K. M., Nicholson, R. I. and Gumbleton, M. 2010. Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Breast Cancer Research and Treatment 119(3), pp. 575-591. (10.1007/s10549-009-0355-8)
2009
- Elsheikh, S. E., Green, A. R., McClelland, R. A., Hutcheson, I. R., Gee, J. M. W., Nicholson, R. I. and Ellis, I. O. 2009. 162 Altered Histone Modifications and their regulating enzymes in Fulvestrant resistant breast cancer cell line In Vitro [Abstract]. Laboratory Investigation 89(S1), pp. 38A-39A. (10.1038/labinvest.2008.132)
- Nicholson, R. I., Hutcheson, I. R., Hiscox, S. E., Taylor, K. M. and Gee, J. M. W. 2009. Experimental endocrine resistance: concepts and strategies. In: Hiscox, S. E., Gee, J. M. W. and Nicholson, R. I. eds. Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential. Dordrecht: Springer, pp. 1-26., (10.1007/978-1-4020-8526-0_1)
- Gee, J. M. W. et al. 2009. The dark side of antihormonal action in breast cancer. In: Hiscox, S. E., Gee, J. M. W. and Nicholson, R. I. eds. Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential. Dordrecht: Springer, pp. 63-84., (10.1007/978-1-4020-8526-0_4)
- Elsheikh, S. E., Green, A. R., McClelland, R. A., Hutcheson, I. R., Gee, J. M. W., Nicholson, R. I. and Ellis, I. O. 2009. Altered Histone Modifications and Their Regulating Enzymes in Fulvestrant Resistant Breast Cancer Cell Line In Vitro [Abstract]. Modern Pathology 22(S1), pp. 38A-39A., article number: 162. (10.1038/modpathol.2008.210)
- Jasani, B., Gee, J. M. W., Hutcheson, I. R., Clarkson, R. W. E., Bartlett, J. and Barrett-Lee, P. 2009. Resistance to HER2-directed trastuzumab therapy in breast cancer. Advances in Breast Cancer 6(3), pp. 11-18.
2008
- Hurtado, A. et al. 2008. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 456(7222), pp. 663-666. (10.1038/nature07483)
- Hurtado, A. et al. 2008. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen [Letter]. Nature 456(7222), pp. 663-666. (10.1038/nature07483)
- Knowlden, J. M., Jones, H. E., Barrow, D., Gee, J. M. W., Nicholson, R. I. and Hutcheson, I. R. 2008. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance. Breast Cancer Research and Treatment 111(1), pp. 79-91. (10.1007/s10549-007-9763-9)
- Bensmail, A., Hutcheson, I. R., Giles, M., Gee, J. M. W. and Nicholson, R. I. 2008. Loss of oestrogen receptor alpha in long-term antioestrogen-resistant cells: reversal by a c-src inhibitor [Abstract]. Breast Cancer Research 10(S2), article number: O3. (10.1186/bcr1883)
- Nicholson, R. I., Hutcheson, I. R., Jones, H. E., Taylor, K. M., Hiscox, S. E. and Gee, J. M. W. 2008. Compensatory signalling induced by anti-hormone and anti-growth factor therapies in breast cancer: a starting point for the development of resistance to targeted therapies.. In: Pasqualini, J. R. ed. Breast cancer: prognosis, treatment and prevention. 2nd ed. London: Informa Healthcare, pp. 123-136.
- Hutcheson, I. R., Gee, J. M. W. and Nicholson, R. I. 2008. MAP Kinase family members and endocrine response and survival in breast cancer. In: Walker, R. A. and Thompson, A. M. eds. Prognostic and predictive factors in breast cancer. 2nd ed.. London: Informa Healthcare, pp. 122-138.
2007
- Hutcheson, I. R., Barrow, D., Hasmann, M. and Nicholson, R. I. 2007. Induction of erbB3/EGFR heterodimers mediates resistance to pertuzumab in a tamoxifen-resistant MCF-7 breast cancer cell line [Abstract]. Molecular Cancer Therapeutics 6(Suppl), pp. 3373S.
- Hutcheson, I. R. et al. 2007. Heregulin beta 1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Breast Cancer Research 9(4), article number: R50. (10.1186/bcr1754)
- Nicholson, R. I., Hutcheson, I. R., Jones, H. E., Hiscox, S. E., Giles, M., Taylor, K. M. and Gee, J. M. W. 2007. Growth factor signalling in endocrine and anti-growth factor resistant breast cancer. Reviews in Endocrine and Metabolic Disorders 8(3), pp. 241-253. (10.1007/s11154-007-9033-5)
2006
- Hutcheson, I. R. et al. 2006. Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy. Endocrine-Related Cancer 13(S1), pp. S89-S97. (10.1677/erc.1.01279)
- Jones, H. E., Gee, J. M. W., Hutcheson, I. R., Knowlden, J. M., Barrow, D. and Nicholson, R. I. 2006. Growth factor receptor interplay and resistance in cancer. Endocrine-Related Cancer 13(S1), pp. S45-S51. (10.1677/erc.1.01275)
- Jones, H. E., Gee, J. M. W., Hutcheson, I. R. and Nicholson, R. I. 2006. Growth factor pathway switching: implications for the use of gefitinib and trastuzumab. Breast Cancer Online 9(7), article number: e27. (10.1017/S1470903106005451)
- Britton, D. J. et al. 2006. Bidirectional cross talk between ER alpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Research and Treatment 96(2), pp. 131-146. (10.1007/s10549-005-9070-2)
2005
- Knowlden, J. M., Hutcheson, I. R., Barrow, D., Gee, J. M. W. and Nicholson, R. I. 2005. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: A supporting role to the epidermal growth factor receptor. Endocrinology 146(11), pp. 4609-4618. (10.1210/en.2005-0247)
- Nicholson, R. I., Hutcheson, I. R., Hiscox, S. E., Knowlden, J. M., Giles, M. G., Barrow, D. and Gee, J. M. W. 2005. Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. Endocrine-Related Cancer 12(S1), pp. S29-S36. (10.1677/erc.1.00991)
- Nicholson, R. I. et al. 2005. Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies. The Journal of Steroid Biochemistry and Molecular Biology 93(2-5), pp. 257-262. (10.1016/j.jsbmb.2004.12.006)
- Gee, J. M. W. and Hutcheson, I. R. 2005. Understanding endocrine resistance: the critical need for sequential samples from clinical breast cancer and novel in vitro models [Viewpoint]. Breast Cancer Research 7(5), pp. 187-189. (10.1186/bcr1289)
2004
- Nicholson, R. I., Staka, C., Boyns, F. E., Hutcheson, I. R. and Gee, J. M. W. 2004. Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy. Endocrine-Related Cancer 11(4), pp. 623-641. (10.1677/erc.1.00778)
- Hutcheson, I. R., Gee, J. M. W., Barrow, D., Jones, H. E., Wakeling, A. E. and Nicholson, R. I. 2004. Treatment of tamoxifen-resistant MCF-7 breast cancer cells with either gefitinib ('Iressa') or trastuzumab (Herceptin((R))) generates cross-resistant phenotypes [Abstract]. Breast Cancer Research and Treatment 88(S1), pp. S145-S146. (10.1007/s10549-004-3602-z)
- Nicholson, R. et al. 2004. Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clinical Cancer Research 10(1), pp. 346s-354s. (10.1158/1078-0432.CCR-031206)
- Nicholson, R. et al. 2004. Chapter 16: beyond antihormones in the targeted therapy of breast cancer. In: Ingle, J. N. and Dowsett, M. eds. Endocrine Therapy for Breast Cancer Proceedings of the 2003 Gleneagles Conference. New York: Marcel Dekker, pp. 249-258.
2003
- Hutcheson, I. R., Knowlden, J. M., Madden, T., Barrow, D., Gee, J. M. W., Wakeling, A. E. and Nicholson, R. I. 2003. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Research and Treatment 81(1), pp. 81-93. (10.1023/A:1025484908380)
- Clark, J. H., Broadley, K. J., Hutcheson, I. R., Nicholson, R. I. and Kidd, E. J. 2003. Expression of adenosine receptors in MCF-7 human breast cancer cells [Abstract]. British Journal of Pharmacology 138, pp. U65.
- Knowlden, J. M. et al. 2003. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144(3), pp. 1032-1044. (10.1210/en.2002-220620)
- Britton, D. J., Hutcheson, I. R., Barrow, D., McClelland, R. A., Gee, J. M. W. and Nicholson, R. I. 2003. Oestrogen receptor phosphorylation in hormone sensitive and anti-hormone resistant breast cancer cells [Abstract]. Breast Cancer Research and Treatment 82(S1), pp. S61. (10.1023/A:1026252325164)
- Nicholson, R. I., Gee, J. M. W., Knowlden, J. M., McClelland, R. A., Madden, T., Barrow, D. and Hutcheson, I. R. 2003. The biology of antihormone failure in breast cancer. Breast Cancer Research and Treatment 80(S1), pp. 29-34. (10.1023/A:1025467500433)
- Hutcheson, I. R., Knowlden, J. M., Barrow, D., Gee, J. M. W., Robertson, J. F., Wakeling, A. E. and Nicholson, R. I. 2003. Heregulin-induced AKT activation promotes growth of gefitinib ('Iressa', ZD1839)-treated, tamoxifen-resistant breast cancer cells [Abstract]. Breast Cancer Research and Treatment 82(S1), pp. S170. (10.1023/A:1026252325164)
- Hutcheson, I. R., Gee, J. M. W. and Nicholson, R. I. 2003. MAP Kinase family members and endocrine response and survival in breast cancer. In: Walker, R. A. ed. Prognostic and Predictive Factors in Breast Cancer. London: Martin Dunitz, pp. 147-166.
2002
- Gee, J. M. W. et al. 2002. ZD1839 ('Iressa') improves the antitumour activity of tamoxifen ('Nolvadex') and ICI 182, 780 ('Faslodex') in antihormone responsive breast cancer [Abstract]. European Journal of Cancer 38(S7), pp. S59. (10.1016/S0959-8049(02)80835-8)
- Nicholson, R. I., Hutcheson, I. R. and Gee, J. M. W. 2002. Targeting of oestrogen and growth factor signalling pathways in the therapy of breast cancer: Implications for chemoprevention [Abstract]. European Journal of Cancer 38(S3), pp. S43-S44. (10.1016/S0959-8049(02)81245-X)
- Clark, J. H., Broadley, K. J., Hutcheson, I. R., Nicholson, R. I. and Kidd, E. J. 2002. Adenosine receptor agonists mediate the phosphorylation of mitogen activated protein kinase (MAPK) in MCF-7 human breast cancer cells [Abstract]. British Journal of Pharmacology 135
- Nicholson, R. I. et al. 2002. Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer. In: Castagnetta, L. et al. eds. Hormone-Related Tumors: Novel Approaches to Prevention and Treatment. Annals of the New York Academy of Sciences Vol. 963. New York: The New York Academy of Sciences, pp. 104-115., (10.1111/j.1749-6632.2002.tb04101.x)
2001
- Nicholson, R. I. et al. 2001. ZD1839 (Iressa) improves the antitumor activity of tamoxifen (Nolvadex) in antihormone-responsive breast cancer cells [Abstract]. Clinical Cancer Research 7(S), pp. 3766S.
- Nicholson, R. I. et al. 2001. Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocrine-Related Cancer 8(3), pp. 175-182. (10.1677/erc.0.0080175)
- Chaytor, A., Marsh, W. L., Hutcheson, I. R. and Griffith, T. M. 2001. Comparison of alpha and beta isoforms of glycyrrhetinic acid and carbenoxolone as inhibitors of EDHF-type relaxation. Presented at: Third International Symposium on Endothelium-Derived Hyperpolarizing Factor, Vaux de Carnay, France, 14-16 June 2000 Presented at Vanhoutte, P. M. ed.EDHF 2000. London: Taylor and Francis pp. 115-126.
1999
- Hutcheson, I. R., Chaytor, A. T., Evans, W. H. and Griffith, T. M. 1999. Nitric oxide independent relaxations to acetylcholine and A23187 involve different routes of heterocellular communication : Role of gap junctions and phospholipase A2. Circulation Research 84(1), pp. 53-63. (10.1161/01.RES.84.1.53)
1996
- Griffith, T. M., Hutcheson, I. R. and Smith, J. A. 1996. Mechanisms of nitric oxide release from rabbit aorta and their modification by hypercholesterolemia. In: Boudoulas, H., Toutouzas, P. K. and Wooley, C. F. eds. Functional abnormalities of the aorta. Armonk, NY: Futura Publishing, pp. 69-92.
1995
- Pugh, N. D., Hutcheson, I. R., Edwards, D. H., Nossen, J. ?., Karlsson, J. O. G. and Griffith, T. M. 1995. Angiographic contrast media relax isolated rabbit aorta through an endothelium-independent mechanism that may not depend on the presence of the iodine atom. British Journal of Radiology 68(805), pp. 23-26. (10.1259/0007-1285-68-805-23)
1994
- Hutcheson, I. R., Warden-Smith, J. and Griffith, T. M. 1994. Abolition of flow-dependent EDRF release before that evoked by agonists in hypercholesterolaemic rabbits. British Journal of Pharmacology 113(1), pp. 190-194.
- Griffith, T. M. and Hutcheson, I. R. 1994. Modulation of endothelium-derived relaxing factor activity by flow. In: Lyall, F. and El Haj, A. J. eds. Biomechanics and cells. Cambridge: Cambridge University Press, pp. 61-80.
1993
- Griffith, T. M., Edwards, D. and Hutcheson, I. R. 1993. Flow pulsatility, arterial chaos and EDRF activity. Presented at: Recent Advances in Coronary Circulation: Two Symposia, Fukushima, Japan, 1993 Presented at Maruyama, Y. et al. eds.Recent Advances in Coronary Circulation: Proceedings of Two Symposia, Fukushima, Japan, 1993. Tokyo: Springer pp. 160-170.
1992
- Hutcheson, I. R. and Griffith, T. M. 1992. Endothelium-derived relaxing factor release is modulated both by the frequency and amplitude of pulsatile flow. Presented at: Second International Meeting on the Biology of Nitric Oxide, London, UK, 1991 Presented at Moncada, S. et al. eds.The Biology of Nitric Oxide, Physiological and Clinical Aspects: Proceedings of the Second International Meeting on the Biology of Nitric Oxide, London, UK, 1991. London: Portland Press pp. 161-164.
1991
- Boughton-Smith, N. K., Hutcheson, I. R., Deakin, A. and Whittle, B. J. R. 1991. Inflammatory and protective mediators in experimental intestinal inflammation. Presented at: 60th Falk Symposium, Freiburg-im-Breisgau, Germany, 18-20 October 1990 Presented at Goebell, H. et al. eds.Inflammatory Bowel Diseases: Progress in Basic Research and Clinical Implications: Proceedings of the 60th Falk Symposium held in Freiburg-im-Breisgau, Germany, October 18-20, 1990. Falk Symposium Vol. 60. Dordrecht: Kluwer Academic pp. 137-152.
- Griffith, T. M., Hutcheson, I. R., Randall, M. D. and Edwards, D. H. 1991. Role of flow in endothelial-mediated responses. Presented at: Third International Symposium on Resistance Arteries, Skörping, Denmark, 21-25 May 1991 Presented at Mulvaney, M. J. et al. eds.Resistance Arteries: Structure and Function: Proceedings of the Third International Symposium on Resistance Arteries, Rebild, Skörping, Denmark, 21-25 May 1991. International Congress Series Vol. 974. Amsterdam: Excerpta Medica pp. 204-207.
Articles
- Fakes, L., Hutcheson, I. and Knowlden, J. 2021. The role of the glucocorticoid receptor in anti-hormone resistance in breast cancer. The British Student Doctor Journal 5(1), pp. 18-31. (10.18573/bsdj.184)
- Gee, J. M. W. et al. 2014. Increased Ret signalling and impact of vandetanib in acquired tamoxifen resistant breast cancer. Cancer Research 74(19), article number: 738. (10.1158/1538-7445.AM2014-738)
- Jordan, N. J. et al. 2014. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro. Breast Cancer Research 16(1), pp. -., article number: R12. (10.1186/bcr3604)
- Hutcheson, I. R. et al. 2011. Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1. Breast Cancer Research 13(2), article number: R29. (10.1186/bcr2848)
- Gee, J. M. W. et al. 2011. Antihormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistance. Hormone Molecular Biology and Clinical Investigation 5(2), pp. 67-77. (10.1515/HMBCI.2011.009)
- Knowlden, J. M., Gee, J. M. W., Barrow, D., Robertson, J. F., Ellis, I. O., Nicholson, R. I. and Hutcheson, I. R. 2011. erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines. Breast Cancer Research 13(5), article number: R93. (10.1186/bcr3018)
- Knowlden, J. M., Gee, J. M. W., Barrow, D., Robertson, J. F., Ellis, I. O., Nicholson, R. I. and Hutcheson, I. R. 2010. O-36 Recruitment of insulin receptor substrate-1 by erbB3 impacts on IGF-IR signalling in oestrogen receptor-positive breast cancer cells [Abstract]. EJC Supplements 8(6), pp. 13-14. (10.1016/j.ejcsup.2010.06.037)
- Knowlden, J. M., Gee, J. M. W., Barrow, D., Robertson, J. F., Ellis, I. O., Nicholson, R. I. and Hutcheson, I. R. 2010. Recruitment of insulin receptor substrate-1 by erbB3 impacts on IGF-IR signalling in oestrogen receptor-positive breast cancer cells [Abstract]. Breast Cancer Research 12(S1), pp. S15. (10.1186/bcr2546)
- Hutcheson, I. R., Goddard, L., Gee, J. M. W., Barrow, D. and Nicholson, R. I. 2010. Fulvestrant-induced expression of erbB3 and erbB4 sensitizes ER-positive breast cancer cells to heregulins [Abstract]. Breast Cancer Research 12(S1), article number: P13. (10.1186/bcr2510)
- Thomas, N. B. P., Hutcheson, I. R., Campbell, L., Gee, J. M. W., Taylor, K. M., Nicholson, R. I. and Gumbleton, M. 2010. Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Breast Cancer Research and Treatment 119(3), pp. 575-591. (10.1007/s10549-009-0355-8)
- Elsheikh, S. E., Green, A. R., McClelland, R. A., Hutcheson, I. R., Gee, J. M. W., Nicholson, R. I. and Ellis, I. O. 2009. 162 Altered Histone Modifications and their regulating enzymes in Fulvestrant resistant breast cancer cell line In Vitro [Abstract]. Laboratory Investigation 89(S1), pp. 38A-39A. (10.1038/labinvest.2008.132)
- Elsheikh, S. E., Green, A. R., McClelland, R. A., Hutcheson, I. R., Gee, J. M. W., Nicholson, R. I. and Ellis, I. O. 2009. Altered Histone Modifications and Their Regulating Enzymes in Fulvestrant Resistant Breast Cancer Cell Line In Vitro [Abstract]. Modern Pathology 22(S1), pp. 38A-39A., article number: 162. (10.1038/modpathol.2008.210)
- Jasani, B., Gee, J. M. W., Hutcheson, I. R., Clarkson, R. W. E., Bartlett, J. and Barrett-Lee, P. 2009. Resistance to HER2-directed trastuzumab therapy in breast cancer. Advances in Breast Cancer 6(3), pp. 11-18.
- Hurtado, A. et al. 2008. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 456(7222), pp. 663-666. (10.1038/nature07483)
- Hurtado, A. et al. 2008. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen [Letter]. Nature 456(7222), pp. 663-666. (10.1038/nature07483)
- Knowlden, J. M., Jones, H. E., Barrow, D., Gee, J. M. W., Nicholson, R. I. and Hutcheson, I. R. 2008. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance. Breast Cancer Research and Treatment 111(1), pp. 79-91. (10.1007/s10549-007-9763-9)
- Bensmail, A., Hutcheson, I. R., Giles, M., Gee, J. M. W. and Nicholson, R. I. 2008. Loss of oestrogen receptor alpha in long-term antioestrogen-resistant cells: reversal by a c-src inhibitor [Abstract]. Breast Cancer Research 10(S2), article number: O3. (10.1186/bcr1883)
- Hutcheson, I. R., Barrow, D., Hasmann, M. and Nicholson, R. I. 2007. Induction of erbB3/EGFR heterodimers mediates resistance to pertuzumab in a tamoxifen-resistant MCF-7 breast cancer cell line [Abstract]. Molecular Cancer Therapeutics 6(Suppl), pp. 3373S.
- Hutcheson, I. R. et al. 2007. Heregulin beta 1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Breast Cancer Research 9(4), article number: R50. (10.1186/bcr1754)
- Nicholson, R. I., Hutcheson, I. R., Jones, H. E., Hiscox, S. E., Giles, M., Taylor, K. M. and Gee, J. M. W. 2007. Growth factor signalling in endocrine and anti-growth factor resistant breast cancer. Reviews in Endocrine and Metabolic Disorders 8(3), pp. 241-253. (10.1007/s11154-007-9033-5)
- Hutcheson, I. R. et al. 2006. Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy. Endocrine-Related Cancer 13(S1), pp. S89-S97. (10.1677/erc.1.01279)
- Jones, H. E., Gee, J. M. W., Hutcheson, I. R., Knowlden, J. M., Barrow, D. and Nicholson, R. I. 2006. Growth factor receptor interplay and resistance in cancer. Endocrine-Related Cancer 13(S1), pp. S45-S51. (10.1677/erc.1.01275)
- Jones, H. E., Gee, J. M. W., Hutcheson, I. R. and Nicholson, R. I. 2006. Growth factor pathway switching: implications for the use of gefitinib and trastuzumab. Breast Cancer Online 9(7), article number: e27. (10.1017/S1470903106005451)
- Britton, D. J. et al. 2006. Bidirectional cross talk between ER alpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Research and Treatment 96(2), pp. 131-146. (10.1007/s10549-005-9070-2)
- Knowlden, J. M., Hutcheson, I. R., Barrow, D., Gee, J. M. W. and Nicholson, R. I. 2005. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: A supporting role to the epidermal growth factor receptor. Endocrinology 146(11), pp. 4609-4618. (10.1210/en.2005-0247)
- Nicholson, R. I., Hutcheson, I. R., Hiscox, S. E., Knowlden, J. M., Giles, M. G., Barrow, D. and Gee, J. M. W. 2005. Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. Endocrine-Related Cancer 12(S1), pp. S29-S36. (10.1677/erc.1.00991)
- Nicholson, R. I. et al. 2005. Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies. The Journal of Steroid Biochemistry and Molecular Biology 93(2-5), pp. 257-262. (10.1016/j.jsbmb.2004.12.006)
- Gee, J. M. W. and Hutcheson, I. R. 2005. Understanding endocrine resistance: the critical need for sequential samples from clinical breast cancer and novel in vitro models [Viewpoint]. Breast Cancer Research 7(5), pp. 187-189. (10.1186/bcr1289)
- Nicholson, R. I., Staka, C., Boyns, F. E., Hutcheson, I. R. and Gee, J. M. W. 2004. Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy. Endocrine-Related Cancer 11(4), pp. 623-641. (10.1677/erc.1.00778)
- Hutcheson, I. R., Gee, J. M. W., Barrow, D., Jones, H. E., Wakeling, A. E. and Nicholson, R. I. 2004. Treatment of tamoxifen-resistant MCF-7 breast cancer cells with either gefitinib ('Iressa') or trastuzumab (Herceptin((R))) generates cross-resistant phenotypes [Abstract]. Breast Cancer Research and Treatment 88(S1), pp. S145-S146. (10.1007/s10549-004-3602-z)
- Nicholson, R. et al. 2004. Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clinical Cancer Research 10(1), pp. 346s-354s. (10.1158/1078-0432.CCR-031206)
- Hutcheson, I. R., Knowlden, J. M., Madden, T., Barrow, D., Gee, J. M. W., Wakeling, A. E. and Nicholson, R. I. 2003. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Research and Treatment 81(1), pp. 81-93. (10.1023/A:1025484908380)
- Clark, J. H., Broadley, K. J., Hutcheson, I. R., Nicholson, R. I. and Kidd, E. J. 2003. Expression of adenosine receptors in MCF-7 human breast cancer cells [Abstract]. British Journal of Pharmacology 138, pp. U65.
- Knowlden, J. M. et al. 2003. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144(3), pp. 1032-1044. (10.1210/en.2002-220620)
- Britton, D. J., Hutcheson, I. R., Barrow, D., McClelland, R. A., Gee, J. M. W. and Nicholson, R. I. 2003. Oestrogen receptor phosphorylation in hormone sensitive and anti-hormone resistant breast cancer cells [Abstract]. Breast Cancer Research and Treatment 82(S1), pp. S61. (10.1023/A:1026252325164)
- Nicholson, R. I., Gee, J. M. W., Knowlden, J. M., McClelland, R. A., Madden, T., Barrow, D. and Hutcheson, I. R. 2003. The biology of antihormone failure in breast cancer. Breast Cancer Research and Treatment 80(S1), pp. 29-34. (10.1023/A:1025467500433)
- Hutcheson, I. R., Knowlden, J. M., Barrow, D., Gee, J. M. W., Robertson, J. F., Wakeling, A. E. and Nicholson, R. I. 2003. Heregulin-induced AKT activation promotes growth of gefitinib ('Iressa', ZD1839)-treated, tamoxifen-resistant breast cancer cells [Abstract]. Breast Cancer Research and Treatment 82(S1), pp. S170. (10.1023/A:1026252325164)
- Gee, J. M. W. et al. 2002. ZD1839 ('Iressa') improves the antitumour activity of tamoxifen ('Nolvadex') and ICI 182, 780 ('Faslodex') in antihormone responsive breast cancer [Abstract]. European Journal of Cancer 38(S7), pp. S59. (10.1016/S0959-8049(02)80835-8)
- Nicholson, R. I., Hutcheson, I. R. and Gee, J. M. W. 2002. Targeting of oestrogen and growth factor signalling pathways in the therapy of breast cancer: Implications for chemoprevention [Abstract]. European Journal of Cancer 38(S3), pp. S43-S44. (10.1016/S0959-8049(02)81245-X)
- Clark, J. H., Broadley, K. J., Hutcheson, I. R., Nicholson, R. I. and Kidd, E. J. 2002. Adenosine receptor agonists mediate the phosphorylation of mitogen activated protein kinase (MAPK) in MCF-7 human breast cancer cells [Abstract]. British Journal of Pharmacology 135
- Nicholson, R. I. et al. 2001. ZD1839 (Iressa) improves the antitumor activity of tamoxifen (Nolvadex) in antihormone-responsive breast cancer cells [Abstract]. Clinical Cancer Research 7(S), pp. 3766S.
- Nicholson, R. I. et al. 2001. Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocrine-Related Cancer 8(3), pp. 175-182. (10.1677/erc.0.0080175)
- Hutcheson, I. R., Chaytor, A. T., Evans, W. H. and Griffith, T. M. 1999. Nitric oxide independent relaxations to acetylcholine and A23187 involve different routes of heterocellular communication : Role of gap junctions and phospholipase A2. Circulation Research 84(1), pp. 53-63. (10.1161/01.RES.84.1.53)
- Pugh, N. D., Hutcheson, I. R., Edwards, D. H., Nossen, J. ?., Karlsson, J. O. G. and Griffith, T. M. 1995. Angiographic contrast media relax isolated rabbit aorta through an endothelium-independent mechanism that may not depend on the presence of the iodine atom. British Journal of Radiology 68(805), pp. 23-26. (10.1259/0007-1285-68-805-23)
- Hutcheson, I. R., Warden-Smith, J. and Griffith, T. M. 1994. Abolition of flow-dependent EDRF release before that evoked by agonists in hypercholesterolaemic rabbits. British Journal of Pharmacology 113(1), pp. 190-194.
Book sections
- Nicholson, R. I., Hutcheson, I. R., Hiscox, S. E., Taylor, K. M. and Gee, J. M. W. 2009. Experimental endocrine resistance: concepts and strategies. In: Hiscox, S. E., Gee, J. M. W. and Nicholson, R. I. eds. Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential. Dordrecht: Springer, pp. 1-26., (10.1007/978-1-4020-8526-0_1)
- Gee, J. M. W. et al. 2009. The dark side of antihormonal action in breast cancer. In: Hiscox, S. E., Gee, J. M. W. and Nicholson, R. I. eds. Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential. Dordrecht: Springer, pp. 63-84., (10.1007/978-1-4020-8526-0_4)
- Nicholson, R. I., Hutcheson, I. R., Jones, H. E., Taylor, K. M., Hiscox, S. E. and Gee, J. M. W. 2008. Compensatory signalling induced by anti-hormone and anti-growth factor therapies in breast cancer: a starting point for the development of resistance to targeted therapies.. In: Pasqualini, J. R. ed. Breast cancer: prognosis, treatment and prevention. 2nd ed. London: Informa Healthcare, pp. 123-136.
- Hutcheson, I. R., Gee, J. M. W. and Nicholson, R. I. 2008. MAP Kinase family members and endocrine response and survival in breast cancer. In: Walker, R. A. and Thompson, A. M. eds. Prognostic and predictive factors in breast cancer. 2nd ed.. London: Informa Healthcare, pp. 122-138.
- Nicholson, R. et al. 2004. Chapter 16: beyond antihormones in the targeted therapy of breast cancer. In: Ingle, J. N. and Dowsett, M. eds. Endocrine Therapy for Breast Cancer Proceedings of the 2003 Gleneagles Conference. New York: Marcel Dekker, pp. 249-258.
- Hutcheson, I. R., Gee, J. M. W. and Nicholson, R. I. 2003. MAP Kinase family members and endocrine response and survival in breast cancer. In: Walker, R. A. ed. Prognostic and Predictive Factors in Breast Cancer. London: Martin Dunitz, pp. 147-166.
- Nicholson, R. I. et al. 2002. Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer. In: Castagnetta, L. et al. eds. Hormone-Related Tumors: Novel Approaches to Prevention and Treatment. Annals of the New York Academy of Sciences Vol. 963. New York: The New York Academy of Sciences, pp. 104-115., (10.1111/j.1749-6632.2002.tb04101.x)
- Griffith, T. M., Hutcheson, I. R. and Smith, J. A. 1996. Mechanisms of nitric oxide release from rabbit aorta and their modification by hypercholesterolemia. In: Boudoulas, H., Toutouzas, P. K. and Wooley, C. F. eds. Functional abnormalities of the aorta. Armonk, NY: Futura Publishing, pp. 69-92.
- Griffith, T. M. and Hutcheson, I. R. 1994. Modulation of endothelium-derived relaxing factor activity by flow. In: Lyall, F. and El Haj, A. J. eds. Biomechanics and cells. Cambridge: Cambridge University Press, pp. 61-80.
Conferences
- Chaytor, A., Marsh, W. L., Hutcheson, I. R. and Griffith, T. M. 2001. Comparison of alpha and beta isoforms of glycyrrhetinic acid and carbenoxolone as inhibitors of EDHF-type relaxation. Presented at: Third International Symposium on Endothelium-Derived Hyperpolarizing Factor, Vaux de Carnay, France, 14-16 June 2000 Presented at Vanhoutte, P. M. ed.EDHF 2000. London: Taylor and Francis pp. 115-126.
- Griffith, T. M., Edwards, D. and Hutcheson, I. R. 1993. Flow pulsatility, arterial chaos and EDRF activity. Presented at: Recent Advances in Coronary Circulation: Two Symposia, Fukushima, Japan, 1993 Presented at Maruyama, Y. et al. eds.Recent Advances in Coronary Circulation: Proceedings of Two Symposia, Fukushima, Japan, 1993. Tokyo: Springer pp. 160-170.
- Hutcheson, I. R. and Griffith, T. M. 1992. Endothelium-derived relaxing factor release is modulated both by the frequency and amplitude of pulsatile flow. Presented at: Second International Meeting on the Biology of Nitric Oxide, London, UK, 1991 Presented at Moncada, S. et al. eds.The Biology of Nitric Oxide, Physiological and Clinical Aspects: Proceedings of the Second International Meeting on the Biology of Nitric Oxide, London, UK, 1991. London: Portland Press pp. 161-164.
- Boughton-Smith, N. K., Hutcheson, I. R., Deakin, A. and Whittle, B. J. R. 1991. Inflammatory and protective mediators in experimental intestinal inflammation. Presented at: 60th Falk Symposium, Freiburg-im-Breisgau, Germany, 18-20 October 1990 Presented at Goebell, H. et al. eds.Inflammatory Bowel Diseases: Progress in Basic Research and Clinical Implications: Proceedings of the 60th Falk Symposium held in Freiburg-im-Breisgau, Germany, October 18-20, 1990. Falk Symposium Vol. 60. Dordrecht: Kluwer Academic pp. 137-152.
- Griffith, T. M., Hutcheson, I. R., Randall, M. D. and Edwards, D. H. 1991. Role of flow in endothelial-mediated responses. Presented at: Third International Symposium on Resistance Arteries, Skörping, Denmark, 21-25 May 1991 Presented at Mulvaney, M. J. et al. eds.Resistance Arteries: Structure and Function: Proceedings of the Third International Symposium on Resistance Arteries, Rebild, Skörping, Denmark, 21-25 May 1991. International Congress Series Vol. 974. Amsterdam: Excerpta Medica pp. 204-207.